ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
Home
Press release
Apr 08, 2020 19:00 JST
Source:
Novotech Health Holdings Pte Ltd
Novotech Data Shows Majority of Australian Sites are Open for Clinical Trial Activity
- Part of New Series of COVID-19 Asia-Pacific Bulletins
SYDNEY, AU, Apr 08, 2020 - (ACN Newswire) - Asia-Pacific's largest specialist biotech CRO Novotech said the top 10 biotech sites in Australia were open for clinical trial activity with many sites modifying their practices to ensure continuity of operations.
View and Download the COVID-19 Australia Data Bulletin here.
https://novotech-cro.com/covid-19-notice
The data is part of a new series prepared for Novotech clients detailing the current status of trials in the Asia-Pacific during the global COVID-19 crisis.
Novotech CEO Dr John Moller said the Bulletin series taps local knowledge of fundamentals in the sector and shows which countries in the region are able to support clinical research for Novotech and its clients during this time.
"While the situation is always evolving, Australia appears to be managing the crisis well. Our sites have changed how they manage trials in line with Australian Government health guidelines and most are still able to deliver the clinical trial services we need for our clients," said Dr Moller. "Study delays caused by COVID-19 can be rapidly addressed by activating new sites in Australia and Asia."
Australia has attractive start-up times, world leading investigators and research teams, and valuable rebates of up to 43.5% on clinical trial spend.
About Novotech
Novotech, established in 1996, is internationally recognized as the leading full-service contract research organization (CRO) in Asia-Pacific. Novotech provides clinical development services across all clinical trial phases and therapeutic areas and has been instrumental in the success of over a thousand Phase I - IV clinical trials for biotech companies.
Novotech obtained the ISO 27001, the best-known standard in the ISO family, providing the requirements for an Information Security Management System. Together with the ISO 9001 Quality Management system, Novotech aims at the highest IT security and quality standards for patients and biotechnology companies. Visit
http://novotech-cro.com
.
For RFP enquiries: Please fill out the form available at
https://novotech-cro.com/talk-to-an-expert
Media Contact
Susan Fitzpatrick-Napier
communications@novotech-cro.com
AU: +61 2 8218 2144
USA: +1 415 951 3228
Asia: +65 3159 3427
Source: Novotech Health Holdings Pte Ltd
Sectors: BioTech, Healthcare & Pharm
Copyright ©2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Latest Release
DENSO, Companies Initiate Demonstration to Expand Automotive Recycling Process
Apr 09, 2024 19:07 JST
Mitsubishi Power Receives Order from HK Electric for Natural-gas-fired GTCC Power Generation Equipment
Apr 09, 2024 15:04 JST
MHI Thermal Systems Adds New KXZ3 Series of Building-use Multi-Split Air- Conditioners Adopting R32 Refrigerant
Apr 09, 2024 13:40 JST
Fujitsu AI transforms manufacturing lines with new quality control system for REHAU
Apr 09, 2024 10:39 JST
NEC white paper proposes comprehensive process workflow for the application of AI-driven personalized cancer vaccines
Apr 08, 2024 13:45 JST
Daihatsu and Toyota to Reform Structures towards the Revitalization of Daihatsu
Apr 08, 2024 13:37 JST
Hitachi Energy and SP Energy Networks to boost renewable energy flow
Apr 05, 2024 17:15 JST
Hitachi Selected as "Excellent TCFD Disclosure" by GPIF's External Asset Managers for the Third Consecutive Year
Apr 05, 2024 17:00 JST
Mitsubishi Corporation: Sale of BMA Coal Assets in Queensland Completed
Apr 03, 2024 19:05 JST
French Sales Subsidiary Eisai S.A.S. to Divest Rights for Loxapac And Parkinane LP to CNX Therapeutics
Apr 03, 2024 16:24 JST
Toyota Completes Toyota Technical Center Shimoyama Research and Development Facility for Making Ever-better Cars
Apr 02, 2024 11:28 JST
Fujitsu signs MoU with Mitsubishi UFJ Financial Group, Inc. to drive nature positive actions
Apr 01, 2024 16:17 JST
Embrace Wellness with Your Cherished Canine at Hyatt Regency Hakone Resort & Spa
Apr 01, 2024 11:00 JST
TOYOTA GAZOO Racing roars to fourth successive Safari triumph
Apr 01, 2024 10:47 JST
Eisai Completes Submission of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA
Apr 01, 2024 09:39 JST
MHI Concludes Positive Impact Finance Agreement
Mar 29, 2024 19:20 JST
Panasonic Energy and Mazda Enter Agreement Towards Supply of Cylindrical Automotive Lithium-ion Batteries
Mar 29, 2024 17:42 JST
Eisai to Divest Rights for Merislon and Myonal in Japan to Kaken Pharmaceutical
Mar 29, 2024 15:51 JST
Eisai's Brain Health Self-Check Tool "NouKNOW" is Certified as "ME-BYO BRAND" by Kanagawa Prefecture
Mar 29, 2024 15:19 JST
Eisai: Discovery Research on Dual Orexin Receptor Antagonist Lemborexant Honored with PSJ Award for Drug Research and Development 2024
Mar 29, 2024 14:32 JST
More Latest Release >>
Related Release
The Evolving Global Landscape in Vaccine Development: Novotech and Endpoints News Webinar
February 15 2023 09:00 JST
Novotech Global Report: Robust Phase 1 Trial Growth Across Asia Pacific
February 10 2023 19:00 JST
Asia Pacific Cell & Gene Research Growing 50% Faster than ROW
February 03 2023 13:00 JST
Novotech Acquires US-based Drug Development Consulting Firm, CBR International
January 12 2023 15:00 JST
Novotech Acquires European CRO, Strengthens Global Operations
January 12 2023 15:00 JST
Novotech is Gold Sponsor at Biotech Showcase 2023
December 20 2022 11:00 JST
Data Shows 50% of New Trials Have Sites in Asia Pacific
December 15 2022 10:00 JST
Novotech Awarded the Asia Pacific CRO of the Year 2022 for Best Practices in Clinical Trials
December 06 2022 11:00 JST
Novotech Chairs BioCentury Summit Workshop on How to Build and Finance an East-West MRCT Strategy
November 11 2022 17:00 JST
Clinical Research Opportunities in China and the Path to USFDA Approval - Whitepaper
October 25 2022 18:00 JST
More Press release >>